Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

20 trials with published results (19%)

Research Maturity

54 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.9%

2 terminated out of 103 trials

Success Rate

96.4%

+9.9% vs benchmark

Late-Stage Pipeline

10%

10 trials in Phase 3/4

Results Transparency

37%

20 of 54 completed with results

Key Signals

20 with results96% success

Data Visualizations

Phase Distribution

77Total
Not Applicable (21)
Early P 1 (1)
P 1 (28)
P 2 (17)
P 3 (5)
P 4 (5)

Trial Status

Completed54
Unknown16
Recruiting12
Active Not Recruiting12
Withdrawn3
Suspended2

Trial Success Rate

96.4%

Benchmark: 86.5%

Based on 54 completed trials

Clinical Trials (103)

Showing 20 of 20 trials
NCT02640014Not ApplicableCompleted

Oral Immunotherapy in Food Allergy in Finland

NCT04339777Phase 2Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT00006150Recruiting

Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)

NCT02579967Phase 2Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT03922724Phase 2Recruiting

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT00001406RecruitingPrimary

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

NCT06173544Not ApplicableCompleted

HIV Engagement and Adolescent Depression Support (HEADS-UP)

NCT05969821Not Yet RecruitingPrimary

Clonal Hematopoiesis of Immunological Significance

NCT03663933Phase 2Active Not Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT06575426Phase 1Recruiting

A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus

NCT03602157Phase 1Active Not Recruiting

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

NCT02690545Phase 1Active Not Recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

NCT03696784Phase 1Active Not Recruiting

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT05516758Phase 2Terminated

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05787574Phase 2Recruiting

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

NCT03016377Phase 1Active Not Recruiting

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

NCT05621317Phase 2Active Not Recruiting

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

NCT06069583Not ApplicableRecruiting

Implementation of Support in the Care of Adults Living With Type 1 Diabetes

NCT05910840Not ApplicableRecruiting

Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care

NCT03672318Phase 1Active Not Recruiting

Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Scroll to load more

Research Network

Activity Timeline